Molecular Dynamics Simulations in Drug Discovery
暂无分享,去创建一个
Yee Siew Choong | Sy-Bing Choi | Beow Keat Yap | Habibah A. Wahab | H. Wahab | S. Choi | Y. Choong | B. Yap
[1] K. Mdluli,et al. Tuberculosis drug discovery and emerging targets , 2014, Annals of the New York Academy of Sciences.
[2] C. E. Barry,et al. The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis. , 2000, Microbes and infection.
[3] K. Forbes,et al. Molecular Evidence for Heterogeneity of the Multiple-Drug-Resistant Mycobacterium tuberculosisPopulation in Scotland (1990 to 1997) , 1999, Journal of Clinical Microbiology.
[4] A. Caflisch,et al. Molecular dynamics in drug design. , 2015, European journal of medicinal chemistry.
[5] V. Uversky,et al. Role of solvent properties of aqueous media in macromolecular crowding effects , 2016, Journal of biomolecular structure & dynamics.
[6] Fouad S. Husseini,et al. Examining the role of protein structural dynamics in drug resistance in Mycobacterium tuberculosis† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc03336b , 2017, Chemical science.
[7] A. Cavalli,et al. Role of Molecular Dynamics and Related Methods in Drug Discovery. , 2016, Journal of medicinal chemistry.
[8] Sanjay Kumar,et al. Ursolic acid and carvacrol may be potential inhibitors of dormancy protein small heat shock protein16.3 of Mycobacterium tuberculosis , 2018, Journal of biomolecular structure & dynamics.
[9] F. Seixas,et al. Mutations in catalase-peroxidase KatG from isoniazid resistant Mycobacterium tuberculosis clinical isolates: insights from molecular dynamics simulations , 2017, Journal of Molecular Modeling.
[10] Aditi Singh,et al. Role of pncA gene mutations W68R and W68G in pyrazinamide resistance , 2018, Journal of cellular biochemistry.
[11] Nanda Ghoshal,et al. 3D-QSAR studies and shape based virtual screening for identification of novel hits to inhibit MbtA in Mycobacterium tuberculosis , 2015, Journal of biomolecular structure & dynamics.
[12] Soumi Sengupta,et al. Structural insight into Mycobacterium tuberculosis maltosyl transferase inhibitors: pharmacophore-based virtual screening, docking, and molecular dynamics simulations , 2015, Journal of biomolecular structure & dynamics.
[13] G. Bai,et al. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. , 1995, The Journal of infectious diseases.
[14] G. Bai,et al. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis , 1995, Antimicrobial agents and chemotherapy.
[15] T. Weisbrod,et al. NADH Dehydrogenase Defects Confer Isoniazid Resistance and Conditional Lethality in Mycobacterium smegmatis , 1998, Journal of bacteriology.
[16] Calvin Yu-Chian Chen,et al. The Inhibition of Folylpolyglutamate Synthetase (folC) in the Prevention of Drug Resistance in Mycobacterium tuberculosis by Traditional Chinese Medicine , 2014, BioMed research international.
[17] K. Drlica,et al. Role of Superoxide in Catalase-Peroxidase-Mediated Isoniazid Action against Mycobacteria , 1998, Antimicrobial Agents and Chemotherapy.
[18] M. Berney,et al. Bactericidal mode of action of bedaquiline. , 2015, The Journal of antimicrobial chemotherapy.
[19] Mary Jackson,et al. Cell Wall Core Galactofuran Synthesis Is Essential for Growth of Mycobacteria , 2001, Journal of bacteriology.
[20] Jacob D. Durrant,et al. Molecular dynamics simulations and drug discovery , 2011, BMC Biology.
[21] M. A. Islam,et al. Identification of promising DNA GyrB inhibitors for Tuberculosis using pharmacophore‐based virtual screening, molecular docking and molecular dynamics studies , 2017, Chemical biology & drug design.
[22] I. H. Lim,et al. Contribution of kasA Analysis to Detection of Isoniazid-Resistant Mycobacterium tuberculosisin Singapore , 1999, Antimicrobial Agents and Chemotherapy.
[23] P. Yogeeswari,et al. Structure-based design of diverse inhibitors of Mycobacterium tuberculosis N-acetylglucosamine-1-phosphate uridyltransferase: combined molecular docking, dynamic simulation, and biological activity , 2015, Journal of Molecular Modeling.
[24] G. Lamichhane,et al. A comparative modeling and molecular docking study on Mycobacterium tuberculosis targets involved in peptidoglycan biosynthesis , 2016, Journal of biomolecular structure & dynamics.
[25] An-Suei Yang,et al. Predicting Ligand Binding Sites on Protein Surfaces by 3-Dimensional Probability Density Distributions of Interacting Atoms , 2016, PloS one.
[26] Rohit Shukla,et al. Distant Phe345 mutation compromises the stability and activity of Mycobacterium tuberculosis isocitrate lyase by modulating its structural flexibility , 2017, Scientific Reports.
[27] Mohammad Imran Siddiqi,et al. Identification of Novel Inhibitors of Mycobacterium tuberculosis PknG Using Pharmacophore Based Virtual Screening, Docking, Molecular Dynamics Simulation, and Their Biological Evaluation , 2015, J. Chem. Inf. Model..
[28] U. Leartsakulpanich,et al. Rational design of InhA inhibitors in the class of diphenyl ether derivatives as potential anti-tubercular agents using molecular dynamics simulations , 2014, SAR and QSAR in environmental research.
[29] Emidio Capriotti,et al. Bioinformatics and variability in drug response: a protein structural perspective , 2012, Journal of The Royal Society Interface.
[30] L. Koymans,et al. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910 , 2007, Proteins.
[31] David E. Shaw,et al. The future of molecular dynamics simulations in drug discovery , 2011, Journal of Computer-Aided Molecular Design.
[32] James C. Sacchettini,et al. Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis , 2000, Journal of bacteriology.
[33] Suresh Kumar Chitta,et al. Comprehensive structural and functional characterization of Mycobacterium tuberculosis UDP-NAG enolpyruvyl transferase (Mtb-MurA) and prediction of its accurate binding affinities with inhibitors , 2011, Interdisciplinary Sciences: Computational Life Sciences.
[34] E. Parker,et al. Quaternary structure is an essential component that contributes to the sophisticated allosteric regulation mechanism in a key enzyme from Mycobacterium tuberculosis , 2017, PloS one.
[35] Stefania Girotto,et al. Reduced Affinity for Isoniazid in the S315T Mutant ofMycobacterium tuberculosis KatG Is a Key Factor in Antibiotic Resistance* , 2003, The Journal of Biological Chemistry.
[36] Tanya Parish,et al. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. , 2002, Microbiology.
[37] Thomas Scior,et al. Elucidating Isoniazid Resistance Using Molecular Modeling , 2009, J. Chem. Inf. Model..
[38] Rohit Shukla,et al. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase , 2018, Journal of biomolecular structure & dynamics.
[39] P. Bharatam,et al. Shape-based virtual screening, docking, and molecular dynamics simulations to identify Mtb-ASADH inhibitors , 2015, Journal of biomolecular structure & dynamics.
[40] F. Kramer,et al. Genotypic Analysis of Mycobacterium tuberculosis in Two Distinct Populations Using Molecular Beacons: Implications for Rapid Susceptibility Testing , 2000, Antimicrobial Agents and Chemotherapy.
[41] Rohit Shukla,et al. Alterations in conformational topology and interaction dynamics caused by L418A mutation leads to activity loss of Mycobacterium tuberculosis isocitrate lyase. , 2017, Biochemical and biophysical research communications.
[42] Hao Fan,et al. Refinement of homology‐based protein structures by molecular dynamics simulation techniques , 2004, Protein science : a publication of the Protein Society.
[43] D. Sriram,et al. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations , 2018, Journal of biomolecular structure & dynamics.
[44] C. Colombo,et al. A Second, Druggable Binding Site in UDP‐Galactopyranose Mutase from Mycobacterium tuberculosis? , 2016, Chembiochem : a European journal of chemical biology.
[45] S. Genheden,et al. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.
[46] Sameer Hassan,et al. Insights into RpoB clinical mutants in mediating rifampicin resistance in Mycobacterium tuberculosis. , 2016, Journal of molecular graphics & modelling.
[47] S. Cole,et al. Missense mutations in the catalase‐peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis , 1995, Molecular microbiology.
[48] Yushir R. Maharaj,et al. Identification of Novel Gyrase B Inhibitors as Potential Anti‐TB drugs: Homology Modelling, Hybrid Virtual Screening and Molecular Dynamics Simulations , 2013, Chemical biology & drug design.
[49] D. Ferguson,et al. Quantitative three dimensional structure linear interaction energy model of 5'-O-[N-(salicyl)sulfamoyl]adenosine and the aryl acid adenylating enzyme MbtA. , 2008, Journal of medicinal chemistry.
[50] L. Hanna,et al. Analysis of interactions of clinical mutants of catalase-peroxidase (KatG) responsible for isoniazid resistance in Mycobacterium tuberculosis with derivatives of isoniazid. , 2017, Journal of global antimicrobial resistance.
[51] S. Sinha,et al. Mechanistic Principles Behind Molecular Mechanism of Rifampicin Resistance in Mutant RNA Polymerase Beta Subunit of Mycobacterium tuberculosis , 2017, Journal of cellular biochemistry.
[52] Vanaja Kumar,et al. Andrographolide: A potent antituberculosis compound that targets Aminoglycoside 2'-N-acetyltransferase in Mycobacterium tuberculosis. , 2015, Journal of molecular graphics & modelling.
[53] P. Kiepiela,et al. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. , 2000, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[54] A. Telenti,et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level , 1997, Journal of clinical microbiology.
[55] A. Nargotra,et al. Discovery of new $${\varvec{Mycobacterium~tuberculosis}}$$Mycobacteriumtuberculosis proteasome inhibitors using a knowledge-based computational screening approach , 2015, Molecular Diversity.
[56] G. Besra,et al. A new interpretation of the structure of the mycolyl-arabinogalactan complex of Mycobacterium tuberculosis as revealed through characterization of oligoglycosylalditol fragments by fast-atom bombardment mass spectrometry and 1H nuclear magnetic resonance spectroscopy. , 1995, Biochemistry.
[57] Helen L Birch,et al. The Mycobacterial Cell Wall--Peptidoglycan and Arabinogalactan. , 2015, Cold Spring Harbor perspectives in medicine.
[58] Giacomo Fiorin,et al. Binding of the antitubercular pro-drug isoniazid in the heme access channel of catalase-peroxidase (KatG). A combined structural and metadynamics investigation. , 2014, The journal of physical chemistry. B.
[59] Active Site Flexibility of Mycobacterium tuberculosis Isocitrate Lyase in Dimer Form. , 2017, Journal of chemical information and modeling.
[60] W L Jorgensen,et al. Rusting of the lock and key model for protein-ligand binding. , 1991, Science.
[61] N. Ghoshal,et al. Integration of ligand and structure based approaches for identification of novel MbtI inhibitors in Mycobacterium tuberculosis and molecular dynamics simulation studies. , 2016, Journal of molecular graphics & modelling.
[62] Jianzhuang Yao,et al. Understanding the Catalytic Mechanism and the Nature of the Transition State of an Attractive Drug-Target Enzyme (Shikimate Kinase) by Quantum Mechanical/Molecular Mechanical (QM/MM) Studies. , 2017, Chemistry.
[63] M. McNeil,et al. Galactofuranose biosynthesis in Escherichia coli K-12: identification and cloning of UDP-galactopyranose mutase , 1996, Journal of bacteriology.
[64] G. Riccardi,et al. The katE gene, which encodes the catalase HPII of Mycobacterium avium , 1996, Molecular microbiology.
[65] J. Aznar,et al. Use of Real-Time PCR and Fluorimetry for Rapid Detection of Rifampin and Isoniazid Resistance-Associated Mutations in Mycobacterium tuberculosis , 2000, Journal of Clinical Microbiology.
[66] A. Garcia,et al. V67L Mutation Fills an Internal Cavity To Stabilize RecA Mtu Intein. , 2017, Biochemistry.
[67] M. Naveen,et al. Probing ligand binding modes of Mycobacterium tuberculosis MurC ligase by molecular modeling, dynamics simulation and docking , 2010, Journal of molecular modeling.
[68] D. Sloan,et al. The role of delamanid in the treatment of drug-resistant tuberculosis , 2015, Therapeutics and clinical risk management.
[69] U. Deva Priyakumar,et al. Dynamics Based Pharmacophore Models for Screening Potential Inhibitors of Mycobacterial Cyclopropane Synthase , 2015, J. Chem. Inf. Model..
[70] W. Jacobs,et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.
[71] P. Ortiz de Montellano,et al. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. , 2007, Bioorganic & medicinal chemistry.
[72] A. Telenti. Genetics of drug resistant tuberculosis , 1998 .
[73] C. G. Mohan,et al. Homology modeling, molecular dynamics and inhibitor binding study on MurD ligase of Mycobacterium tuberculosis , 2012, Interdisciplinary Sciences: Computational Life Sciences.
[74] K. Herrmann,et al. THE SHIKIMATE PATHWAY. , 1999, Annual review of plant physiology and plant molecular biology.
[75] M. Tamoi,et al. Crystal structure of the catalase–peroxidase KatG W78F mutant from Synechococcus elongatus PCC7942 in complex with the antitubercular pro‐drug isoniazid , 2015, FEBS letters.
[76] S. Irle,et al. Elucidating the structural basis of diphenyl ether derivatives as highly potent enoyl-ACP reductase inhibitors through molecular dynamics simulations and 3D-QSAR study , 2014, Journal of Molecular Modeling.
[77] Amit Nargotra,et al. Benzothiazole Derivative as a Novel Mycobacterium tuberculosis Shikimate Kinase Inhibitor: Identification and Elucidation of Its Allosteric Mode of Inhibition , 2016, J. Chem. Inf. Model..
[78] A. Singh,et al. Insight into the structural flexibility and function of Mycobacterium tuberculosis isocitrate lyase. , 2015, Biochimie.
[79] M. Halim,et al. Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA). , 2017, Journal of molecular graphics & modelling.
[80] Ying Zhang,et al. New drug candidates and therapeutic targets for tuberculosis therapy. , 2006, Drug discovery today.
[81] Karina S Machado,et al. Effect of the explicit flexibility of the InhA enzyme from Mycobacterium tuberculosis in molecular docking simulations , 2011, BMC Genomics.
[82] M. Tamoi,et al. The crystal structure of isoniazid‐bound KatG catalase‐peroxidase from Synechococcus elongatus PCC7942 , 2015, The FEBS journal.
[83] Luiz Augusto Basso,et al. Combining molecular dynamics and docking simulations of the cytidine deaminase from Mycobacterium tuberculosis H37Rv , 2012, Journal of Molecular Modeling.
[84] Gaurava Srivastava,et al. Molecular investigation of active binding site of isoniazid (INH) and insight into resistance mechanism of S315T-MtKatG in Mycobacterium tuberculosis. , 2017, Tuberculosis.
[85] Richard E. Lee,et al. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. , 2016, Advanced drug delivery reviews.
[86] O. N. de Souza,et al. Observed crowding effects on Mycobacterium tuberculosis 2-trans-enoyl-ACP (CoA) reductase enzyme activity are not due to excluded volume only , 2017, Scientific Reports.
[87] R. Vishwakarma,et al. Computationally Guided Identification of Novel Mycobacterium tuberculosis GlmU Inhibitory Leads, Their Optimization, and in Vitro Validation. , 2016, ACS combinatorial science.
[88] R. Sarma,et al. Cell wall permeability assisted virtual screening to identify potential direct InhA inhibitors of Mycobacterium tuberculosis and their biological evaluation , 2018, Journal of biomolecular structure & dynamics.